RhumbLine Advisers’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $588K | Sell |
215,996
-6,518
| -3% | -$21.7K | ﹤0.01% | 2630 |
|
|
2026
Q2 | $834K | Buy |
+222,514
| New | +$850K | ﹤0.01% | 2435 |
|
|
2024
Q3 | – | Sell |
-1,291
| Closed | -$1.58K | – | 4228 |
|
|
2024
Q2 | $1.58K | Hold |
1,291
| – | – | ﹤0.01% | 4204 |
|
|
2024
Q1 | $2.81K | Hold |
1,291
| – | – | ﹤0.01% | 4054 |
|
|
2023
Q4 | $2K | Hold |
1,291
| – | – | ﹤0.01% | 4092 |
|
|
2023
Q3 | $1.66K | Hold |
1,291
| – | – | ﹤0.01% | 4128 |
|
|
2023
Q2 | $2.22K | Buy |
+1,291
| New | +$2.14K | ﹤0.01% | 4203 |
|
|
2022
Q2 | – | Sell |
-67,376
| Closed | -$180K | – | 3124 |
|
|
2022
Q1 | $180K | Buy |
67,376
+428
| +0.6% | +$1.64K | ﹤0.01% | 2782 |
|
|
2021
Q4 | $290K | Sell |
66,948
-985
| -1% | -$5.77K | ﹤0.01% | 2716 |
|
|
2021
Q3 | $346K | Buy |
67,933
+3,757
| +6% | +$20.1K | ﹤0.01% | 2706 |
|
|
2021
Q2 | $406K | Buy |
64,176
+3,190
| +5% | +$24.8K | ﹤0.01% | 2656 |
|
|
2021
Q1 | $471K | Buy |
60,986
+1,845
| +3% | +$14.6K | ﹤0.01% | 2521 |
|
|
2020
Q4 | $387K | Buy |
59,141
+3,310
| +6% | +$23.6K | ﹤0.01% | 2550 |
|
|
2020
Q3 | $371K | Sell |
55,831
-7,790
| -12% | -$57.8K | ﹤0.01% | 2427 |
|
|
2020
Q2 | $530K | Buy |
63,621
+2,956
| +5% | +$27.5K | ﹤0.01% | 2315 |
|
|
2020
Q1 | $465K | Sell |
60,665
-1,690
| -3% | -$11.8K | ﹤0.01% | 2193 |
|
|
2019
Q4 | $518K | Buy |
62,355
+1,147
| +2% | +$7.74K | ﹤0.01% | 2341 |
|
|
2019
Q3 | $452K | Buy |
61,208
+921
| +2% | +$9.08K | ﹤0.01% | 2368 |
|
|
2019
Q2 | $676K | Buy |
60,287
+2,500
| +4% | +$26.2K | ﹤0.01% | 2238 |
|
|
2019
Q1 | $621K | Sell |
57,787
-1,356
| -2% | -$20K | ﹤0.01% | 2236 |
|
|
2018
Q4 | $893K | Buy |
59,143
+21,402
| +57% | +$318K | ﹤0.01% | 2064 |
|
|
2018
Q3 | $698K | Buy |
37,741
+689
| +2% | +$15.7K | ﹤0.01% | 2148 |
|
|
2018
Q2 | $847K | Buy |
37,052
+8,100
| +28% | +$207K | ﹤0.01% | 2086 |
|
|
2018
Q1 | $824K | Buy |
28,952
+200
| +0.7% | +$5.71K | ﹤0.01% | 2027 |
|
|
2017
Q4 | $607K | Sell |
28,752
-4,245
| -13% | -$88K | ﹤0.01% | 2159 |
|
|
2017
Q3 | $600K | Buy |
32,997
+480
| +1% | +$7.49K | ﹤0.01% | 2221 |
|
|
2017
Q2 | $504K | Buy |
32,517
+10,607
| +48% | +$160K | ﹤0.01% | 2300 |
|
|
2017
Q1 | $378K | Buy |
21,910
+872
| +4% | +$11.5K | ﹤0.01% | 2384 |
|
|
2016
Q4 | $231K | Buy |
21,038
+3,812
| +22% | +$46.2K | ﹤0.01% | 2615 |
|
|
2016
Q3 | $270K | Buy |
17,226
+2,300
| +15% | +$27.8K | ﹤0.01% | 2534 |
|
|
2016
Q2 | $152K | Buy |
+14,926
| New | +$170K | ﹤0.01% | 2830 |
|
Other funds holding CTMX
RhumbLine Advisers's CTMX Position: Q3 2026 in Review
RhumbLine Advisers reduced its CytomX Therapeutics (CTMX) stake by 2.9% in Q3 2026, selling an estimated $21.7K and leaving 215,996 shares worth $588K. The position accounts for ﹤0.01% of the portfolio, ranked #2630.
RhumbLine Advisers first reported a position in CTMX in Q2 2016 and has held it in 31 quarters since. The position peaked at $893K in Q4 2018. 69 funds tracked by Wall St. Rank hold CTMX as of Q3 2026.
- RhumbLine Advisers held 215,996 shares of CytomX Therapeutics worth $588K as of Q3 2026.
- RhumbLine Advisers sold 6,518 CytomX Therapeutics shares in Q3 2026, an estimated $21.7K.
- CytomX Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #2630 holding.
- RhumbLine Advisers first reported a position in CytomX Therapeutics in Q2 2016 and has held it in 31 quarters since.
- RhumbLine Advisers's CytomX Therapeutics position peaked at $893K in Q4 2018.
- 69 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2026.
Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.